VX‐765 ameliorates renal injury and fibrosis in diabetes by regulating caspase‐1‐mediated pyroptosis and inflammation

• Published in: Journal of diabetes investigation Vol. 13; no. 1; pp. 22 - 33
• Main Authors: Wen, Si, Deng, Fei, Li, Lulu, Xu, Li, Li, Xin, Fan, Qiuling
• Format: Journal Article
• Language: English
• Published: Japan John Wiley & Sons, Inc 01.01.2022; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Antibodies; Antigens; Apoptosis; Balloon treatment; Caspase; Caspase 1 - metabolism; Caspase‐1; CD45 antigen; Cell culture; Cell Culture Techniques; Cell death; Cell membranes; Collagen (type I); Creatinine; Cytotoxicity; Dehydrogenases; Diabetes; Diabetes mellitus; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - pathology; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - pathology; Diabetic nephropathy; Dipeptides - pharmacology; Enzyme-linked immunosorbent assay; Epilepsy; Fibronectin; Fibrosis; Flow cytometry; Glucose; Glucose - pharmacology; GSDMD; Humans; Immunoprecipitation; Immunoreactivity; Inflammation; Kidney - pathology; Kidney Tubules - drug effects; Kidney Tubules - pathology; Laboratory animals; Male; Mice; Microscopy; Nephropathy; Original; para-Aminobenzoates - pharmacology; Pyroptosis; Pyroptosis - drug effects; Renal cortex; Renal function; Urine; VX‐765; United States > US; China; GSDMD; Diabetic nephropathy; Inflammation; Pyroptosis; VX-765; Caspase-1

Introduction As a lytic inflammatory cell death, pyroptosis has been recently described but has not been unequivocally elucidated in diabetic nephropathy (DN). VX‐765 is a safe and effective inhibitor of caspase‐1, that was well tolerated in a phase II clinical trial in patients with epilepsy, but i...